Adverum Biotech Stock Price, News & Analysis

Adverum Biotechnologies (NASDAQ:ADVM) announced accelerated progress in its pivotal Phase 3 ARTEMIS trial for Ixo-vec, a potential one-time gene therapy treatment for wet age-related macular degeneration (wet AMD). The company will complete patient screening by September 30, 2025, ahead of schedule.

The trial is expected to achieve full enrollment of at least 284 patients in Q4 2025, earlier than the previous target of Q1 2026. This acceleration has moved the topline data readout forward to Q1 2027. ARTEMIS is comparing a single administration of Ixo-vec (6E10 vg/eye) to aflibercept (2mg) given every 8 weeks in both treatment-naïve and previously treated patients.

Adverum Biotechnologies (Nasdaq: ADVM) has granted inducement awards to two new employees under its 2017 Inducement Plan. The awards include non-qualified stock options to purchase 16,860 shares and restricted stock units (RSUs) for 8,430 shares of common stock.

The stock options have an exercise price of $3.08 per share and vest over four years, with 25% vesting in the first year and the remainder monthly over three years. The RSUs vest over three years, with one-third vesting annually. Both awards require continuous employment for vesting.

Adverum Biotechnologies (Nasdaq: ADVM) reported significant progress in its ARTEMIS Phase 3 trial for wet AMD treatment, with enrollment exceeding expectations and completion anticipated in Q1 2026. The company secured a $10 million private placement from Frazier Life Sciences.

Key highlights include: upcoming LUNA 2-year follow-up data in Q4 2025, strong retina specialist enthusiasm for gene therapy (preferred by 50% of specialists), and anticipated ARTEMIS topline data in 1H 2027. Financial results show $44.4 million in cash as of June 30, 2025, with a net loss of $49.2 million ($2.34 per share) for Q2 2025.

[ "Strong enrollment progress in ARTEMIS Phase 3 trial, ahead of schedule", "Secured $10 million private placement from Frazier Life Sciences", "50% of retina specialists view gene therapy as most exciting advancement in wet AMD treatment", "Potential for Ixo-vec to offer lifelong, best-in-class therapy for wet AMD" ]

Adverum Biotechnologies (NASDAQ:ADVM) announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Laurent Fischer, MD, President and CEO, along with Szilárd Kiss, MD, Distinguished Professor of Ophthalmology and Board Member, will engage in a fireside chat on August 13, 2025, at 9:00 AM EDT.

The presentation will be accessible via live webcast through Adverum's website investor section, with a replay available for at least 30 days after the event.

Adverum Biotechnologies (NASDAQ: ADVM) has granted inducement awards to two new employees under its 2017 Inducement Plan, as approved by the company's Compensation Committee. The awards include non-qualified stock options to purchase 9,740 shares at $2.22 per share and 4,870 restricted stock units (RSUs). The stock options vest over four years with 25% vesting after one year and the remainder monthly over three years, while RSUs vest over three years with one-third vesting annually. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements and are subject to continuous employment requirements.

Adverum Biotechnologies (NASDAQ: ADVM) reported Q1 2025 financial results and pipeline updates for its gene therapy treatment Ixo-vec. The company launched ARTEMIS, the first registrational intravitreal gene therapy trial for wet AMD, enrolling both treatment-experienced and treatment-naïve patients. At ARVO 2025, they presented groundbreaking data showing cell-level mapping of Ixo-vec's effectiveness 3.5 years post-administration. Key financials show a net loss of $47.0 million ($2.25 per share) compared to $27.1 million in Q1 2024. Cash position stands at $83.1 million, expected to fund operations into H2 2025. R&D expenses increased to $28.7 million from $15.4 million year-over-year. The company plans to initiate its second Phase 3 trial, AQUARIUS, in H2 2025 and present two-year LUNA follow-up data in Q4 2025.

Adverum Biotechnologies (NASDAQ: ADVM) has granted inducement awards to seven new employees under its 2017 Inducement Plan. The awards include non-qualified stock options to purchase 32,620 shares of common stock at $3.33 per share and restricted stock units (RSUs) for 16,310 shares. The stock options vest over four years with 25% vesting in the first year and the remainder monthly over three years. The RSUs vest over three years, with one-third vesting annually. These grants were approved as inducement material for new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Adverum Biotechnologies (ADVM) has reported its Q4 and full year 2024 financial results, highlighting significant progress with its Ixo-vec gene therapy for wet AMD treatment. The company has initiated ARTEMIS, their first pivotal trial, which will evaluate Ixo-vec in approximately 284 patients.

The company's cash position stood at $125.7 million as of December 31, 2024, expected to fund operations into H2 2025. Q4 2024 resulted in a net loss of $40.9 million ($1.96 per share), compared to $24.5 million in Q4 2023. R&D expenses increased to $24.1 million from $15.3 million, while G&A expenses rose to $18.5 million from $11.7 million year-over-year.

Key upcoming milestones include the initiation of the global AQUARIUS Phase 3 trial in H2 2025 and presentation of Phase 2 LUNA two-year follow-up data in Q4 2025.

Adverum Biotechnologies (NASDAQ: ADVM) has announced an inducement grant for a new employee under its 2017 Inducement Plan. The Compensation Committee approved non-qualified stock options to purchase 30,000 shares of common stock at an exercise price of $3.83 per share, matching Adverum's closing price on the grant date.

The stock options will vest over a four-year period, with 25% vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months, contingent on the employee's continued service with Adverum. The grant was approved in accordance with Nasdaq Listing Rule 5635(c)(4).